Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia

Endocrine Practice

Volumn 9, Issue 1, 2003, Pages 22-25

  Case, Christopher C ^a   Vassilopoulou Sellin, Rena ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE;

ADULT; ARTICLE; CASE REPORT; CHEILITIS; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG EFFICACY; ECZEMA; ERYTHEMA; FEMALE; GLUCAGONOMA; HEMANGIOPERICYTOMA; HUMAN; HYPERGLUCAGONEMIA; HYPOGLYCEMIA; INSULINOMA; MALE; PANCREAS ISLET CELL TUMOR; RASH; SYMPTOMATOLOGY; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0038159430     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.9.1.22     Document Type: Article

References (21)

1. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer. 1998;82:1585-1592.
2. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321:306-320.
3. Samaan NA, Pham FK, Sellin RV, Fernandez JF, Benjamin RS. Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med. 1990;113:404-406.
4. Glucagon data. In: Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, 2001: 1725-1727.
5. Hutchison TA, Shanan DR, eds. DRUGDEX System. Vol 110. Greenwood Village, CO: MICROMEDEX, Inc., 2001.
6. Vassilopoulou-Sellin R. Glucagon treatment in NICTH [letter]. J Clin Endocrinol Metab. 1996;81:1671.
7. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syph. 1942;45:1069-1075.
8. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2:347-361.
9. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome: clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75:53-63.
10. Weitzel D, Wittenborg A, Wuppermann T, Freyschmidt J. Acute subclavian and axillary vein thrombosis during long-term glucagon infusion [article in German]. Med Welt. 1973;24:791-792.
11. Koch-Weser J. Potentiation by glucagon of the hypoprothrombinemic action of warfarin. Ann Intern Med. 1970; 72:331-335.
12. Leichter SB. Clinical and metabolic aspects of glucagonoma. Medicine (Baltimore). 1980;59:100-113.
13. Norton JA, Kahn CR, Schiebinger R, Gorschboth C, Brennan MF. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med. 1979;91: 213-215.
14. Sinclair SA, Reynolds NJ. Necrolytic migratory erythema and zinc deficiency. Br J Dermatol. 1997;136:783-785.
15. Marinkovich MP, Botella R, Datloff J, Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol. 1995;32: 604-609.
16. Goodenberger DM, Lawley TJ, Strober W, et al. Necrolytic migratory erythema without glucagonoma. Arch Dermatol. 1979;115:1429-1432.
17. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol. 1998;38(5 Pt 2):866-873.
18. Shepherd ME, Raimer SS, Tyring SK, Smith EB. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol. 1991;25(5 Pt 2):925-928.
19. Smith AP, Doolas A, Staren ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol. 1996;61:306-309.
20. Bloom SR, Polak JM. Glucagonoma syndrome. Am J Med. 1987;82(5B):25-36.
21. Barber SG, Hamer JD. Skin rash in patient receiving glucagon [letter]. Lancet. 1976;2:1138.